Sanofi and Recipharm announce transfer of Holmes Chapel Manufacturing site
Recipharm and Sanofi announced today that they have signed an agreement to transfer the Holmes Chapel site from global healthcare leader, Sanofi, to leading pharmaceutical contract development and manufacturing organisation, Recipharm.
“Holmes Chapel brings Recipharm an ideal opportunity to accelerate its offering to customers with access to novel respiratory products. As an already successful CMO with several clients, we look forward to introducing new contracts to Holmes Chapel by utilising our growing franchise in development services. Treatments for asthma and chronic obstructive pulmonary disease (COPD) are growing at a fast rate and we see many opportunities. The experienced management team and staff have already successfully attracted new customers and we look forward to building on this from the well invested facility” said Thomas Eldered, CEO of Recipharm.
“We are delighted that the Holmes Chapel site is being bought by a company who will further develop the site and its employees, and bring opportunities to utilise the existing technologies and capabilities” said Volker Keuth, Head of Cartridge Division & Emerging Markets, at Sanofi.
The Holmes Chapel manufacturing facility is one of the leading sites of its type in Europe and is home to a team of more than 450 specialist employees. All employees will automatically transfer to Recipharm.
The transaction is expected to close in Q4 2018, after customary licences and permissions have been obtained.
For media enquiries, please contact:
Lindsay Baldry at ramarketing: firstname.lastname@example.org, + 44 191 222 1242, www.ramarketingpr.com, Twitter: @ramarketingpr, Facebook: /ramarketingpr, LinkedIn: /ramarketing
Louise Brant, Corporate Communications Lead, Sanofi, telephone: +44 148 355 4074, Louise.email@example.com
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing around 5,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s turnover is approximately SEK 5.3 billion and the company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.
For more information on Recipharm and our services, please visit www.recipharm.com
Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.
Sanofi, Empowering Life
Recipharm AB (publ)
Corporate identity number 556498-8425
Address Box 603, SE-101 32 Stockholm, Sweden, Telephone +46 8 602 52 00